Clareo Health | CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Anthera Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Fulfill at least 4 diagnostic criteria for SLE defined by American College of Rheumatology
Active SLE disease as defined by SELENA-SLEDAI score ≥10 despite on-going stable corticosteroid therapy
Positive for anti-double stranded DNA (anti-dsDNA) and low complement
Subjects with stable nephritis may be enrolled
18 years of age or older
You may not be if
Severe active central nervous system lupus
Malignancy within past 5 years
Known to be positive for HIV and/or positive at the screening visit for hepatitis B, or hepatitis C
Comorbidities that would interfere with evaluations of study drug effect
Active infection requiring hospitalization or treatment with parenteral antibiotics within the past 60 days or history of repeated herpetic viral infections
History of active tuberculosis or a history of tuberculosis infection
